NVZMF (Novonesis (Novozymes) B) Other Stockholders Equity: $-480 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
90 GF Score
Price $66.44
GF Value $63.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Other Stockholders Equity?

Novonesis (Novozymes) B NVZMF +2.08% 90 Other Stockholders Equity is $-480 Mil as of Jun. 2026. GuruFocus rates NVZMF with a GF Score™ of 90/100 and a GF Value™ of $63.82 (Fairly Valued). The stock has 5 warning signs investors should review.

Novonesis (Novozymes) B's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $-480 Mil.

Novonesis (Novozymes) B's quarterly Other Stockholders Equity increased from Dec. 2025 ($-504 Mil) to Mar. 2026 ($-342 Mil) but then declined from Mar. 2026 ($-342 Mil) to Jun. 2026 ($-480 Mil).

Novonesis (Novozymes) B's annual Other Stockholders Equity increased from Dec. 2023 ($-50 Mil) to Dec. 2024 ($19 Mil) but then declined from Dec. 2024 ($19 Mil) to Dec. 2025 ($-504 Mil).

Novonesis (Novozymes) B Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Other Stockholders Equity Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.12 30.57 -50.23 18.64 -503.60

Novonesis (Novozymes) B Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -492.31 -493.62 -503.60 -342.32 -479.50
NVZMF
90GF Score
Novonesis (Novozymes) B NVZMF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-480 Mil mean?
Novonesis (Novozymes) B (NVZMF) has a Other Stockholders Equity of $-480 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Other Stockholders Equity too high?
Novonesis (Novozymes) B's current Other Stockholders Equity is $-480 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Other Stockholders Equity compare to LIN and SHW?
Novonesis (Novozymes) B's Other Stockholders Equity of $-480 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Chemicals company?
A good Other Stockholders Equity depends on the Chemicals industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Other Stockholders Equity is $-480 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $63.82, compared to a current price of $66.44 — trading 4.1% above its estimated fair value. The current Other Stockholders Equity is $-480 Mil. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Other Stockholders Equity is $-480 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $66.44 is trading 4.1% above its estimated GF Value™ of $63.82. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Other Stockholders Equity: $-480 Mil
  • GF Value™: $63.82 vs. price of $66.44 (4.1% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis (Novozymes) B is a Danish biotechnology company formed in 2024 through the merger of Novozymes and Chr. Hansen. It is a leading global producer of industrial enzymes and microbial solutions, serving industries such as household care, food and beverages, bioenergy, agriculture and animal feed, and technical and pharmaceutical applications. Its biological products help customers improve yield, efficiency, and performance while reducing energy use and waste. The company operates across two main business areas: enzymes and microorganisms, spanning food and health biosolutions and agriculture, bioenergy, and technical biosolutions. Headquartered in Denmark, Novonesis employs more than 11,000 people and operates numerous research, development, and application centers alongside manufacturing sites worldwide. Revenue is generated primarily through the sale of enzyme and microbial products to industrial and agricultural customers globally, supported by ongoing research and application development.
90GF Score

Get the complete analysis for NVZMF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.44
Price
$63.82
GF Value